Summary of Discussion: Respiratory Syncytial Virus (RSV) Vaccine Safety and Pharmacovigilance

RSV vaccines for adults remain relatively new. This meeting presented public health, researchers, vaccine manufacturers, regulators, and policy makers to discuss current knowledge gaps about vaccine safety, need and consideration for pharmacovigilance for novel adult RSV vaccines and leveraging strengths of Canadian vaccine safety surveillance systems to address knowledge gaps.